Natera (NASDAQ:NTRA) Stock: Insider Steven Leonard Chapman Sells 3,430 Shares

Key Points

• Natera CEO Steven Chapman sold 3,430 shares for approximately $1.46 million at an average price of $426.34. The sale was made under a Rule 10b5-1 plan to cover tax withholding related to vested equity awards, leaving him with 91,232 shares.
• Natera shares rose to $436, near their 52-week high of $437.41, while the company’s latest quarterly results showed revenue growth of 37.7% and revenue of $752.75 million, exceeding analyst expectations.
• Institutional investors own 99.90% of Natera, and analysts maintain a generally positive outlook with a “Moderate Buy” consensus rating, although upcoming third-quarter results and valuation concerns could increase volatility.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Chapman sold 3,430 shares of the firm's stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $426.34, for a total transaction of $1,462,346.20. Following the completion of the transaction, the chief executive officer directly owned 91,232 shares of the company's stock, valued at $38,895,850.88. This represents a 3.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 27th, Steven Chapman sold 2,264 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $919,184.00.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The shares were sold at an average price of $413.31, for a total value of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total value of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The shares were sold at an average price of $266.39, for a total value of $819,415.64.

Natera Price Performance

Shares of NTRA traded up $11.58 during trading hours on Thursday, reaching $436.00. The company's stock had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The company has a 50 day moving average of $375.27 and a two-hundred day moving average of $265.54.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company posted ($0.74) earnings per share. Equities research analysts expect that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in Natera during the second quarter valued at about $2,962,770,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Natera by 1.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company's stock valued at $238,334,000 after acquiring an additional 11,793 shares during the last quarter. Maverick Capital Ltd. raised its stake in shares of Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company's stock valued at $234,315,000 after acquiring an additional 227,605 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company's stock valued at $226,220,000 after acquiring an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in Natera in the 2nd quarter worth approximately $199,960,000. Institutional investors own 99.90% of the company's stock.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Morgan Stanley upped their price target on shares of Natera from $355.00 to $435.00 and gave the stock an "overweight" rating in a research note on Monday, October 12th. Guggenheim boosted their target price on Natera from $360.00 to $475.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Barclays boosted their target price on Natera from $340.00 to $475.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. Robert W. Baird set a $348.00 target price on Natera in a research report on Friday, August 7th. Finally, Citigroup raised their price target on Natera from $365.00 to $480.00 and gave the stock a "buy" rating in a research note on Tuesday, October 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.